Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Avidity Biosciences Inc
(NQ:
RNA
)
44.98
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Avidity Biosciences Inc
< Previous
1
2
3
4
5
Next >
The Analyst Landscape: 7 Takes On Avidity Biosciences
August 12, 2024
Via
Benzinga
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
August 09, 2024
RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
August 09, 2024
Via
Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
August 09, 2024
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.
Via
Investor's Business Daily
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
July 24, 2024
These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market.
Via
InvestorPlace
(RNA) - Analyzing Avidity Biosciences's Short Interest
June 20, 2024
Via
Benzinga
Chart Of The Day: Avidity Biosciences - Something's Up?
June 14, 2024
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
Via
Talk Markets
A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts
June 10, 2024
Via
Benzinga
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
July 23, 2024
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
July 18, 2024
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via
Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
July 01, 2024
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged.
Via
Benzinga
Topics
ETFs
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Navigating 7 Analyst Ratings For Avidity Biosciences
May 03, 2024
Via
Benzinga
Where Avidity Biosciences Stands With Analysts
April 11, 2024
Via
Benzinga
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
June 16, 2024
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry.
Via
Benzinga
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
June 14, 2024
Via
Benzinga
Crude Oil Moves Higher; Vera Bradley Shares Slide
June 12, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 12, 2024
Via
Benzinga
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher
June 12, 2024
Via
Benzinga
Why Avidity Biosciences Shares Are Trading Higher Wednesday
June 12, 2024
The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran.
Via
Benzinga
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
June 12, 2024
Via
Benzinga
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point
June 12, 2024
The company is working on a treatment for a rare form of muscular dystrophy.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 12, 2024
Via
Benzinga
2 Potentially High-Reward Growth Stocks to Buy Right Now
May 29, 2024
These two biotechnology stocks could be gearing up for a run.
Via
The Motley Fool
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
May 23, 2024
Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention.
Via
InvestorPlace
RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
RNA stock results show that Avidity Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
April 18, 2024
Via
Benzinga
Topics
ETFs
This Demand Zone In S&P 500 Needs To Hold
April 03, 2024
Find out the demand zone that the S&P 500 needs to hold to avoid a meaningful pullback.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
March 14, 2024
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.